Skip to main content
Shari Goldfarb, MD, Oncology, New York, NY

ShariBethGoldfarbMD

Oncology • New York, NY

Breast Cancer, Hematologic Oncology

Assistant Attending, Medicine, Memorial Sloan-Kettering Cancer Center

Request Appointment

Overview of Dr. Goldfarb

Dr. Shari Goldfarb is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center, Memorial Hospital for Cancer and allied Diseases, and New York-Presbyterian Hospital. She received her medical degree from SUNY Upstate Medical University and has been in practice 13 years. Dr. Goldfarb accepts several types of health insurance, listed below. She is one of 495 doctors at Memorial Sloan Kettering Cancer Center and one of 90 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Oncology. She has more than 60 publications and over 500 citings.

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2007 - 2010
  • NYU Grossman School of Medicine
    NYU Grossman School of MedicineResidency, Internal Medicine, 2004 - 2007
  • SUNY Upstate Medical University
    SUNY Upstate Medical UniversityClass of 2004

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2021 - Present
  • NY State Medical License
    NY State Medical License 2006 - 2026
  • NJ State Medical License
    NJ State Medical License 2020 - 2025
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Ultra-low doses of TX-004HR to improve symptoms of vulvar and vaginal atrophy (VVA) while maintaining serum levels of estradiol within the normal postmenopausal range. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

  • Sermonix's Lasofoxifene Improves Vaginal/Vulvar Symptoms Relative to Fulvestrant in ELAINE 1 Study of Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2- Breast Cancer and an ESR1 Mutation
    Sermonix's Lasofoxifene Improves Vaginal/Vulvar Symptoms Relative to Fulvestrant in ELAINE 1 Study of Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2- Breast Cancer and an ESR1 MutationMarch 6th, 2023
  • Sermonix to Present Poster Comparing Lasofoxifene and Fulvestrant Effect on Vaginal Health at International Society for the Study of Women's Sexual Health Annual Meeting 2023
    Sermonix to Present Poster Comparing Lasofoxifene and Fulvestrant Effect on Vaginal Health at International Society for the Study of Women's Sexual Health Annual Meeting 2023February 8th, 2023
  • Breast Cancer Rates Among Younger Women Rise While Rates Among Older Women Fall
    Breast Cancer Rates Among Younger Women Rise While Rates Among Older Women FallOctober 18th, 2022
  • Join now to see all

Insurance Accepted

  • Aetna Choice POS II
    Aetna HMO
    BCBS Blue Card PPO
    CIGNA HMO
    CIGNA Open Access
    CIGNA PPO
    Empire BCBS HMO
    Empire BCBS PPO
    GHI PPO
    Great West PPO
    Humana ChoiceCare Network PPO
    MVP Healthcare PPO
    Oxford Health Freedom
    Oxford Health Liberty
    QualCare HMO
    QualCare PPO
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
  • Please verify your coverage with the provider's office directly when scheduling an appointment

Dr. Shari Goldfarb, Dr. Shari Goldfarb, MD, Dr. S Goldfarb, Dr. Shari Beth Goldfarb